Syncom Formulations (India) Peer Comparison

Snapshot Summary

In the Pharmaceuticals & Drugs sector, Syncom Formulations (India) Ltd. shows a mixed performance with notable growth in revenue, but lower profitability and efficiency metrics compared to peers. Companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. lead in profitability, while Syncom appears to be overvalued relative to its peers' financial health and growth potential.

• Cipla Ltd. and Dr. Reddy's Laboratories Ltd. are the most profitable with the highest ROE and EPS.
• Syncom has the lowest profitability metrics and is overvalued with a PE ratio of 32.28 compared to peers.
• Cipla is the best value pick with low PE and high profitability ratios.

• Cipla Ltd.: Highest profitability with a PE of 23.73 and ROE of 16.63.
• Dr. Reddy's Laboratories Ltd.: Strong profitability metrics with the lowest PE at 15.50 and high ROE at 21.76.

Stocks	CMP	Market Cap	P/E	ROCE (%)	Debt/Equity
SYNCOMF	₹16.78	₹1,577.32Cr	32.28	11.05%	0.25
SUNPHARMA	₹1,563.35	₹3,75,099.26Cr	87.59	17.60%	0.04
DIVISLAB	₹6,091.05	₹1,61,698.50Cr	73.20	16.46%	-
CIPLA	₹1,587.60	₹1,28,217.27Cr	23.73	22.77%	0.01
TORNTPHARM	₹3,581.55	₹1,21,215.77Cr	61.53	24.28%	0.57
DRREDDY	₹1,280.30	₹1,06,835.27Cr	15.50	26.86%	0.07
MANKIND	₹2,518.95	₹1,03,926.59Cr	55.18	28.38%	0.02

Explore

Watchlists

Command Palette

Syncom Formulations (India) Peer Comparison

Snapshot Summary